Congress Materials – European Academy of Neurology (EAN 2026)
2026 Congress of the European Academy of Neurology | Jun 27-20 | Geneva, Switzerland
Assessment of Sustained Health-Related-Quality-of-Life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
John Vissing, Kavita Gandhi, Sheryl Pease, Ibrahim Turkoz, Marie Fitzgibbon, Geoffroy Coteur, Wisam Karmous, Nolan Campbell, Sindhu Ramchandren, Elena Cortés-Vicente
Corticosteroid Use in Nipocalimab-treated Japanese Patients with Generalized Myasthenia Gravis: Phase 3 Vivacity-MG3 Open-Label Extension Study
Carlo Antozzi, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Marie Fitzgibbon, Sindhu Ramchandren, Hiroyuki Murai
Effect of Nipocalimab on Pathogenic IgG and Complement Markers in Patients with Seropositive gMG: Exploratory Analysis in Vivacity-MG3 Study
Silke Miller, Jingyue Xi, Yanfei Zhang, Ruben Faelens, Marie Fitzgibbon, Sindhu Ramchandren, Sarah Hoffmann
Effect of Nipocalimab on Sustained Myasthenia Gravis Control During Infections: Post-hoc Analysis of the Vivacity-MG3 Study
Carlo Antozzi, Gonçalo M.C. Rodrigues, Marie Fitzgibbon, Robert Edwards, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Ghazala S. Hayat
Efficacy of Nipocalimab in Adult Patients with None-to-Mild Ocular Manifestations of Generalized Myasthenia Gravis in Phase 3 VIVACITY-MG3
Kristl G. Claeys, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Marie Fitzgibbon, Sindhu Ramchandren
Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis: Post Hoc Analysis of VIVACITY-MG3
Carlo Antozzi, Wim Noel, Marie Fitzgibbon, Wisam Karmous, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Elena Cortés-Vicente
Efficacy of Nipocalimab in Patients with Lower Baseline Score of Myasthenia Gravis Activity of Daily Living in VIVACITY-MG3 study
Carlo Antozzi, Wim Noel, Wisam Karmous, Marie Fitzgibbon, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren
Indirect Comparison of Nipocalimab Safety versus FcRn Blockers, C5 Complement Inhibitors, Rituximab and IVIg in Generalized Myasthenia Gravis
Saiju Jacob, Brian Hutton, Suzy Van Sanden, Tom Denee, Wisam Karmous, Joris Diels, Kavita Gandhi, Mahmoud Hashim, Nils Erik Gilhus
One-Year Burden of Crises and Exacerbations in Myasthenia Gravis: Real-World Evidence from France (RELIEF Study)
Jean-Baptiste Noury, Didier Theis, Erika Guyot, Maeva Nolin, Manon Belhassen, Ingrid Rodriguez, Julia Meijer, Laurène Gautier, Julien Dupin, Thierry Gendre
Pregnancy Enhanced Tracking with Neonatal and Infant Assessment (PETUNIA): Design of a Safety Study for Nipocalimab in Generalized Myasthenia Gravis
Neelam Goyal, Christopher J. Robinson, Christiane Schneider-Gold, Diana E. Clements, Marie Fitzgibbon, Ibrahim Turkoz, Lorraine S. Gentner, Toyin Adewole, Lisa Schwartz, Melanie H. Jacobson
Progression and Exacerbation Timing in Myasthenia Gravis: Real-World Evidence from France (RELIEF Study)
Thierry Gendre, Didier Theis, Erika Guyot, Maeva Nolin, Manon Belhassen, Ingrid Rodriguez, Julia Meijer, Laurène Gautier, Julien Dupin, Jean-Baptiste Noury
Quality of Life in Generalized Myasthenia Gravis Patients Achieving Sustained versus Transient Clinical Outcomes in the Phase 3 Vivacity-MG3 Trial
John Vissing, Carlo G. Antozzi, Kelly G. Gwathmey, Kavita Gandhi, Ibrahim Turkoz, Sheryl Pease, Nolan Campbell
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.